texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Dallas Clinical Trials

Texas Oncology cancer centers in Dallas participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Dallas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Dallas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Dallas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Dallas area and talk to you doctor to determine which clinical trial is right for you.

Biliary Tract Cancer

Indication: Biliary Tract Cancer

Location: Innovative Clinical Trial Center

Phase:

Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN SUBJECTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AFTER ONE LINE OF SYSTEMIC THERAPY. View

Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: A randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase:

Title: Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER) View

Hematologic

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase:

Title: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A View

Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Miscellaneous

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Other

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Renal Cancer

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) View

Indication: Renal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Sarcoma

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Skin Cancer

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (0103-020) View

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Sherman

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (0103-020) View

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Mesquite

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Testicular Cancer

Indication: Testicular Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thymomas

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thyroid Cancer

Indication: Thyroid Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Urothelial Cancer

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: Protocol 42756493BLC2001 A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Uterine Cancer

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Vaginal Cancer

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Innovative Clinical Trial Center

Indication: Biliary Tract Cancer

Location: Innovative Clinical Trial Center

Phase:

Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN SUBJECTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AFTER ONE LINE OF SYSTEMIC THERAPY. View

Texas Oncology-Baylor Charles A. Sammons Cancer Center

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Denton South

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Skin Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (0103-020) View

Indication: Testicular Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: Protocol 42756493BLC2001 A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Texas Oncology-Flower Mound

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Renal Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Skin Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Medical City Dallas Building C

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Medical City Dallas Building D

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase:

Title: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A View

Texas Oncology-Medical City Dallas Radiation Oncology

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Mesquite

Indication: Skin Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Mesquite

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Methodist Dallas Cancer Center

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase:

Title: Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER) View

Texas Oncology-Plano East

Indication: Renal Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Skin Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Plano West

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Renal Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (0103-020) View

Indication: Testicular Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Presbyterian Cancer Center Dallas

Indication: Renal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) View

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: A randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Renal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Skin Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Sherman

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Renal Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER) View

Indication: Skin Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Sherman

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Wichita Falls Cancer Center

Indication: Skin Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

No Phase

Indication: Biliary Tract Cancer

Location: Innovative Clinical Trial Center

Phase:

Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN SUBJECTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AFTER ONE LINE OF SYSTEMIC THERAPY. View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Renal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) View

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: A randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent View

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (BRJ) with Metastatic Breast Cancer View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase:

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAS-102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND VARYING DEGREES OF RENAL IMPAIRMENT View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma View

Indication: Other

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase (SNDX-275-0602) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced SolidTumors View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease (E7080-M001-221) View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer View

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Compassionate Use of Abemaciclib for a Single Patient (LF) with Metastatic Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Compassionate Use of Neratinib for a Single Patient (CR) with Metastatic Breast Cancer View

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: Analysis of Patient Comprehension of Disease Prognosis in Patients with Metastatic Lung and Pancreatic Cancer View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase:

Title: AZD6094 (Savolitinib) D5082C00003 A Phase III, Open Label, Randomised, Controlled, Multi-Centre, Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced Or Metastatic Papillary Renal Cell Carcinoma (PRCC) View

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase:

Title: Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER) View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase:

Title: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A View

Phase I

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Sarcoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Phase I/II

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Phase II

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (0103-020) View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: Protocol 42756493BLC2001 A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (0103-020) View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Skin Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Phase III

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Solid Tumors

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Renal Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Phase III/IV

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Phase IV

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Sherman

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Mesquite

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View